HIV (Human Immunodeficiency Virus) and AIDS (Acquired Immune Deficiency Syndrome) are global health problems. As such, there is growing demand to improve the effectiveness and simplify tests for HIV diagnostics, without compromising on the patient’s quality of life.
Wilmington, Delaware, United States, Transparency Market Research Inc. – HIV (Human Immunodeficiency Virus) and AIDS (Acquired Immune Deficiency Syndrome) are global health problems. As such, there is growing demand to improve the effectiveness and simplify tests for HIV diagnostics, without compromising on the patient’s quality of life.
Read Report Overview - https://www.transparencymarketresearch.com/hiv-aids-diagnostics-market.html
This growing demand for efficacious treatment in the HIV/AIDS diagnostics landscape has led stakeholders in the healthcare industry to leverage medical infrastructure with new discoveries and innovations in POC (Point of Care) instruments via research & development. POC devices are easy to operate and maintain, and can be conveniently transported. POC tests also eliminate the need for laboratory technicians to operate the devices.
Recent developments in the HIV/AIDS diagnostics landscape have resulted in tremendous improvements in Point of Care (POC) technologies. These advancements in technologies have led to the adoption of ART (Antiretrovial Therapy) treatment. ART treatment is playing an important role in helping stakeholders provide high-quality diagnostics, especially in low- and middle-income countries (LMICs). As such, in the HIV/AIDS diagnostics landscape, stakeholders are scaling up operations due to the increased demand for CD4 (Cluster of Differentiation 4) tests, viral load (VL) testing, HIV rapid diagnostic tests (RDTs), and HIV early-infant diagnosis (EID) tests.
Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=26582
Ultrasensitive HIV Tests Kits Serve as Promising Alternative for Early HIV Detection
In the HIV/AIDS diagnostics landscape, there is growing demand for fourth- and fifth-generation treatment options. Recent developments in Enzyme Linked Immunosorbent Assay (ELISA) and HIV test kits have shown that, the effective performance of the test kits depends upon the genetic diversities of people living in different countries of the world. Thus, stakeholders must consider the evaluation of HIV test kits on the basis of the country’s genetic diversity.
Latest research studies in the HIV/AIDS diagnostics landscape have stated the results of Genscreen ULTRA HIV Ag-Ab and Bioelisa — both HIV test kits. These test kits are highly sensitive in detecting HIV, and are effective in detecting almost all seroconversion panels. Apart from HIV test kits, nucleic acid tests also dominate the HIV/AIDS diagnostics market. Viral capsid protein p24 serves as an efficacious alternative as an early biomarker of the infection. As such, emerging and ultrasensitive assays are showing promising treatment approaches for stakeholders.
Strengthening Diagnostics Capacity by Decentralizing HIV Care and Technological Advancements
Trends in the HIV/AIDS diagnostics landscape will be influenced by the need to reduce visits to hospitals and diagnostic laboratories, a shift in monitoring HIV from CD4 to VL testing, approbation of the latest pediatric guidelines and adherence to WHO (World Health Organization) HIV testing norms. Thus, stakeholders in the HIV/AIDS diagnostics landscape must focus on increasing the availability of POC technologies for VL, and meet the increasing demand for EID tests. However, they will likely face the challenge of lack of developmental and technological innovations in LMICs. This gap of technological advancement can be fulfilled by strengthening diagnostic capacity in decentralizing HIV care and treatment solutions for technologically-backward regions.
As far as HICs (high-income countries) are concerned, ongoing research & development efforts are being navigated towards identifying the needs of patients, complying with government regulations, and driving innovations in the design and testing of diagnostic products in the HIV/AIDS diagnostics landscape. For instance, in February 2019, Hologic, Inc. — a leading medical technology company, announced the launch of Aptima HIV-1 Quant Dx Assay, which is a one-of-its-kind dual-claim assay used for early infant diagnosis (EID) and viral load (VL).
Request for Custom Research – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=26582
HIV/AIDS Diagnostics Market: Overview
- The global HIV/AIDS diagnostics market is projected to be valued at ~US$ 3.2 Bn in 2019.
- The HIV/AIDS diagnostics market is expected to expand at a CAGR of ~9% from 2019 to 2027.
- The global HIV/AIDS diagnostics market is expected to reach a value of ~US$ 6.2 Bn in 2019.
HIV/AIDS Diagnostics: Related Factors
High prevalence of HIV, rise in adoption rate of HIV self-tests, increase in awareness about HIV diagnosis, surge in the rate of infection among young adults, and rise in co-infections are the key factors that fuel the growth of the global HIV/AIDS diagnostics market.
Blood tests are the most common method to diagnose human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS). These tests look for antibodies to the virus that are present in the blood of infected individuals.
HIV infection is often diagnosed through rapid diagnostic tests (RDTs), which detect the presence or absence of HIV antibodies. Most often, these tests provide same-day test results, which are essential for early diagnosis, treatment, and care.
Ask for References – https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=26582
Global HIV/AIDS Diagnostics Market: Drivers & Restraints
HIV continues to be a public health issue. According to the WHO, HIV is a major global public health issue, having claimed more than 32 million lives. In 2018, 770,000 people succumbed to HIV-related causes, globally. There were approximately 37.9 million people living with HIV at the end of 2018, with 1.7 million people becoming newly infected in 2018. A majority of the affected population lives in lower- and middle-income countries. Of the diagnosed population, around 23.3 million people are undergoing antiretroviral therapy. Hence, rise in the prevalence of HIV is projected to increase the demand for HIV/AIDS diagnostics, which, in turn, is anticipated to boost the growth of the HIV/AIDS diagnostics market.
In 2016, the WHO published the first global guidelines on HIV self-testing, in which HIV self-testing was recommended to be offered as an additional approach to HIV testing services. Fifty nine countries have adopted HIV self-testing policies, while many others are currently developing them. The market for HIV self-tests continues to evolve rapidly. According to the WHO, global HIV self-test procurement volumes exceeded 1 million tests in 2017, and are estimated to increase rapidly to 16.4 million by the end of 2020. As such, the HIV/AIDS diagnostics market is projected to grow at a fast rate.
Several government organizations and agencies have developed public awareness campaigns for HIV diagnosis, treatment, and care. A campaign sponsored by the CDC called ‘Doing It’ creates awareness about the importance of HIV testing for all age groups. The campaign focuses on high-risk groups in the U.S. Another campaign named ‘One Test. Two Lives’ encourages healthcare providers to test pregnant women for HIV to reduce the number of infants born with HIV. These campaigns and initiatives boost the growth of the global market.
Limited skilled human resources, lack of equipment, inadequate quality control programs, and weak supply chains for reagents and consumables are posing major hindrances in the HIV/AIDS diagnostics market. Laboratories should have facilities appropriate for the type of work conducted. These facilities should permit maintaining experimental arrangements for extended periods of time during ongoing research projects. Testing technologies are useful in a broad spectrum of resource-limited settings, but these have disadvantages. With the exception of rapid tests, other diagnostic technologies are costly, take hours to perform, and require highly-skilled technicians and dedicated laboratory spaces.
Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=26582
HIV/AIDS Diagnostics Market: Key Players
The report provides the company profiles section that includes key information about the major players in the global HIV/AIDS diagnostics market.
Key players in the HIV/AIDS diagnostics market have been profiled based on key attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies.
Leading players analyzed in the global HIV/AIDS diagnostics market report include
- Hologic, Inc.
- Abbott, Bio-Rad Laboratories
- F. Hoffmann-La Roche Ltd.
- OraSure Technologies, Inc.
- Siemens Healthineers
- Chembio Diagnostic Systems
- Danaher Corporation
- Becton
- Dickinson and Company.
More Trending Reports by Transparency Market Research –
Cervical Cancer Diagnostic Tests Market: The global cervical cancer diagnostic tests market is expected to exceed value of US$ 13.6 Bn by the end of 2031.
Central Lab Market: The global central lab market is expected to reach the value of US$ 4 Bn by the end of 2031.
In Vitro Diagnostics Market: The global in vitro diagnostics market is expected to reach the value of US$ 115.43 Bn by the end of 2028.
ASRs and RUOs Market: The U.S. ASRs and RUOs market is expected to surpass the value of US$ 5.3 Bn by the end of 2031.
Companion Diagnostics Market: The global companion diagnostics market is expected to reach the value of US$ 9.30 Bn by the end of 2028.
Respiratory Panel Testing Market: The Europe and Middle East & Africa respiratory panel testing market is expected to surpass the value of US$ 3.1 Bn by the end of 2031.
Direct-to-Consumer Laboratory Testing Market: The direct-to-consumer laboratory testing market in North America is projected to expand at a CAGR of 22.6% during the forecast period.
Dermal Fillers Market: The global dermal fillers market is estimated to register growth at a CAGR of 10.3% during the forecast period from 2022 to 2031.
About Us
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ
Contact
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com